What led you into lung cancer research? I started my career as a Pulmonologist and my major interest was thoracic oncology since the beginning. This was mainly due to the possibility to merge clinic and research. Having this background is somewhat easier to deal with these patients, who are frequently heavy smokers (or former smokers), with comorbidities that are part of the daily clinical practice for a Pulmonologist.
You have been involved in the AURA study. Could you tell us a little about the aims & findings of the study? The AURA trials are another important piece in the thoracic oncology field looking In the last 15 years, several attempts were made in order to introduce new treatments and new approaches in the lung cancer therapeutic algorithm. Several improvements have been done, but unfortunately there are many more failures already in Phase I and, even worse, in Phase III trials. In fact, it could happen that some positive signals are coming from a Phase II study, inducing pharma companies and researchers to move forward in the development.
What are the most promising new drugs in development for lung cancer?
In my opinion, mainly focusing on advanced NSCLC, there are at least three turning points in the last 15 years: the introduction of the concept of histology as a predictive factor due to the results of the pemetrexed registration trial in first line; the start of precision medicine in thoracic oncology with the identification of two druggable biomarkers (EGFR and Alk) and the new world of immunotherapy starting from the results of nivolumab in squamous carcinoma up to pembrolizumab data in the first line. 
Part of your research has focused on gender differences in lung cancer. Could you tell us about your work with Women Against Lung Cancer in Europe ?
Women Against Lung Cancer in Europe (WALCE) was founded in 2006 to raise awareness with regard to the increase of incidence and mortality of lung cancer among women. Ten years later, WALCE is a European Advocacy Group doing information, prevention, support for all the patients with lung cancer and their families. WALCE is cooperating with other Advocacies across the world and with scientific Societies dealing with thoracic malignancies.
Where do you see your own research heading over the next 10 years? I will continue with my commitment in primary prevention because smoking cessation is the real way to ensure that lung cancer could become a rare disease. Many results have been reached in the multidisciplinary approach but many others are still to be done. In the precision medicine, we are just at the beginning and many efforts need to be made to get more drugs for further targets. Immunotherapy is for sure a great innovation for thoracic malignancies but many sides remain obscure in this context 
